Form 8-K - Current report:
SEC Accession No. 0001437749-23-002493
Filing Date
2023-02-03
Accepted
2023-02-03 17:20:20
Documents
14
Period of Report
2023-02-03
Items
Item 1.02: Termination of a Material Definitive Agreement

Document Format Files

Seq Description Document Type Size
1 FORM 8-K mbrx20230203_8k.htm   iXBRL 8-K 23615
6 moleculin01.jpg GRAPHIC 5411
  Complete submission text file 0001437749-23-002493.txt   169800

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA mbrx-20230203.xsd EX-101.SCH 3600
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE mbrx-20230203_def.xml EX-101.DEF 11531
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE mbrx-20230203_lab.xml EX-101.LAB 15413
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mbrx-20230203_pre.xml EX-101.PRE 11687
8 EXTRACTED XBRL INSTANCE DOCUMENT mbrx20230203_8k_htm.xml XML 2562
Mailing Address 5300 MEMORIAL DRIVE SUITE 950 HOUSTON TX 77007
Business Address 5300 MEMORIAL DRIVE SUITE 950 HOUSTON TX 77007 713-300-5160
Moleculin Biotech, Inc. (Filer) CIK: 0001659617 (see all company filings)

IRS No.: 474671999 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37758 | Film No.: 23587386
SIC: 2834 Pharmaceutical Preparations